SCHEMBL5541397

SCHEMBL5541397

[CH2]c1ccccc1NCc1ccc(OC(F)(F)F)cc1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.42
MEN1 O00255 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRM5 P08912 1/20 0.40
EPHX2 P34913 3/20 0.39
NR1H4 Q96RI1 1/20 0.39
TRPV1 Q8NER1 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
PDE2A O00408 1/20 0.36
TACR1 P25103 1/20 0.36
KCNH2 Q12809 1/20 0.36
OPRM1 P35372 1/20 0.35
CTSC P53634 2/20 0.35
KDR P35968 2/20 0.35
RAF1 P04049 1/20 0.35
LCK P06239 1/20 0.35
RET P07949 1/20 0.35
CYP3A4 P08684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536417 0.79 KDM1A (0.46) MAPTMEN1HTTRAB9AKMT2A
SCHEMBL5543549 0.78 KDM5A (0.53) MEN1KMT2AKDRFLT1
SCHEMBL5544240 0.77 LMNA (0.47) MAPTMEN1HTTKMT2ACYP3A4
SCHEMBL5543496 0.76 HDAC3 (0.48) MAPTMEN1HTTRAB9AKMT2A
SCHEMBL2094276 0.75 GPR3 (0.49) CHRM5TDP1CTSCKIF11GPR3
SCHEMBL5540133 0.72 EPHX2 (0.44) CHRM5EPHX2NR1H4TRPV1TDP1
SCHEMBL5540126 0.72 EPHX2 (0.44) CHRM5EPHX2NR1H4TRPV1TDP1
SCHEMBL5545072 0.72 L3MBTL1 (0.42) MAPTMEN1HTTKMT2ACYP3A4
SCHEMBL543035 0.71 GPR3 (0.44) RAB9ACHRM5TDP1CTSCCYP3A4
SCHEMBL2090668 0.70 TRPV1 (0.46) CHRM5EPHX2NR1H4TRPV1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 MAPT 4117/4885MEN1 3295/4885HTT 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.